Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...
Hosted on MSN20d
Jazz Pharmaceuticals bids for Chimerix in $935m dealJazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately $935m in cash. The deal, disclosed on Wednesday 5 March, will see Jazz pay ...
Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million in cash to gain access to its lead drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback